Does increased utilization of early revascularization and guideline-recommended therapy improve survival and reduce recurrent cardiovascular events in patients with first-time myocardial infarction?
Nationwide Danish data from 2000 to 2017 shows a temporal trend of improved survival and reduced cardiovascular events after first-time MI, reinforcing the real-world effectiveness of guideline-recommended revascularization and pharmacotherapy.
The results from the current study portrait the risk of all-cause mortality, recurrent MI, and first-time admission for HF in a real-life setting with a very high utilization of early revascularization and guideline-recommended pharmacological therapy. We observed a temporal trend of improved survival, reduced risk of recurrent MI, as well as reduced risk of first-time admission for HF after first-time MI from 2000 through 2017. We observed an increase in the overall use of revascularization, as well as early revascularization and use of guideline-recommended pharmacotherapy. Our study reveals important results from real-life, nationwide data, showing a reduced risk of cardiovascular outcomes after first-time MI during the past 20 years. Current guidelines are based on results from clinical trials. Our real-life results add additionally important knowledge on patients' prognosis after first-time MI and underline the importance of treating MI according to guideline recommendations.
Ravn et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: